Epitomee Medical Ltd (EPIT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Epitomee Medical Ltd (EPIT) has a cash flow conversion efficiency ratio of -0.416x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-12.78 Million ≈ $-34.27K USD) by net assets (ILA30.72 Million ≈ $82.35K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See EPIT net asset quality score to measure how much of total assets are equity-financed.
Epitomee Medical Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Epitomee Medical Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Epitomee Medical Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Epitomee Medical Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Epitomee Medical Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Andromeda Metals Ltd
AU:ADN
|
-0.013x |
|
Thai O.P.P. Public Company Limited
BK:TOPP
|
0.030x |
|
China Crystal New Material
KQ:900250
|
0.045x |
|
Renovaro Biosciences Inc
NASDAQ:RENB
|
0.085x |
|
CompuLab Ltd
TA:CLAB
|
0.080x |
|
Duc Long Gia Lai Group JSC
VN:DLG
|
-0.523x |
|
ilShinbiobase Co. Ltd
KQ:068330
|
0.053x |
|
Black Dragon Gold Corp
AU:BDG
|
0.214x |
Annual Cash Flow Conversion Efficiency for Epitomee Medical Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Epitomee Medical Ltd from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Epitomee Medical Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA33.95 Million ≈ $91.02K |
ILA-8.29 Million ≈ $-22.23K |
-0.244x | -7.30% |
| 2023-12-31 | ILA34.80 Million ≈ $93.30K |
ILA-7.92 Million ≈ $-21.24K |
-0.228x | +4.69% |
| 2022-12-31 | ILA39.45 Million ≈ $105.75K |
ILA-9.42 Million ≈ $-25.26K |
-0.239x | -121.08% |
| 2021-12-31 | ILA53.30 Million ≈ $142.89K |
ILA-5.76 Million ≈ $-15.44K |
-0.108x | -106.37% |
| 2020-12-31 | ILA3.98 Million ≈ $10.66K |
ILA6.75 Million ≈ $18.09K |
1.697x | +519.62% |
| 2019-12-31 | ILA6.89 Million ≈ $18.49K |
ILA-2.79 Million ≈ $-7.47K |
-0.404x | -- |
About Epitomee Medical Ltd
Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. It offers capsules, which are polymer-based scaffold for controlled delivery of therapies along the GI tract for weight management and biologics delivery. The company was incorporated in 2005 and is based in Caesarea, Israel.